Document is current
Any future updates will be listed below
-
Authors
Kessel, Johanna
Braner, Axel
Diricks, Margo
Walther, Thomas
Holubec, Tomas
Werner, Rudolf
Hogardt, Michael
Wichelhaus, Thomas A.
Niemann, Stefan
Moter, Annette
Friesen, Inna
Wetzstein, Nils https://orcid.org/0000-0002-5589-4668
-
Funding
Funding for this research was provided by:
Universitätsklinikum Frankfurt
- License Information
-
More Information
Article History
Received: 13 January 2025
Accepted: 30 March 2025
First Online: 7 April 2025
Declarations
:
: The patient signed informed consent for publication of her case history.
: Johanna Kessel, Axel Braner, Margo Diricks, Thomas Walther, Michael Hogardt, Stefan Niemann, Inna Friesen, and Nils Wetzstein have nothing to disclose.Tomas Holubec has received consultancy fees and honoraria from Abbott, USA; Artivion, USA; Fehling, Germany and Getinge, Sweden, outside the submitted work. Rudolf Werner has received speaker honoraria from Novartis/AAA and PentixaPharm, reports advisory board work for Novartis/AAA and Bayer and in involved in 68Ga-PentixaFor PET Imaging in PAN Cancer (FORPAN), sponsored and planned by PentixaPharm. Thomas A. Wichelhaus reports research grants from BMBF, JPIAMR, Deutsche Krebshilfe, MSD as well as speaker fees and consulting honoraria from Landesärztekammer Hessen, Insmed, Osartis, all outside the submitted work. Annette Moter holds shares in MiKi Analytics GmbH and runs Moter Diagnostics private practice.
